David Kenigsberg Appointed as Chief Medical Officer
Pulse Biosciences, Inc. (NASDAQ: PLSE), a leader in innovative cardiac care technology, is pleased to announce the appointment of Dr. David Kenigsberg, M.D. as their Chief Medical Officer for Electrophysiology. This strategic move comes as the company continues to advance its pioneering Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, which holds great promise for patients suffering from atrial fibrillation.
Enhancing Clinical Development
Dr. Kenigsberg will replace Andrea Natale, M.D., who will transition to a medical advisor role within the company, joining established advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. Together, these leaders will play vital roles in supporting the Pulse Biosciences nano-PFA 360 Cardiac Catheter's ongoing clinical efforts.
Innovative Technology Insight
Dr. Kenigsberg shared his excitement about the potential of the nano-PFA technology, emphasizing the unique 360 catheter design that has shown remarkable efficacy in isolating pulmonary veins. He expressed admiration for the catheter's performance and looks forward to contributing to the robust clinical data that could significantly enhance atrial fibrillation treatment methodologies.
The Vision of Atrial Fibrillation Treatment
Having dedicated his career to the field of cardiac electrophysiology, Dr. Kenigsberg founded Florida Heart Rhythm Specialists and the Ft. Lauderdale Heart & Rhythm Surgical Center. His extensive background includes serving as the Medical Director of the Electrophysiology Lab at HCA Westside Medical Center since 2007. He has an impressive portfolio of scholarly publications and has been an essential contributor to numerous clinical trials exploring advanced ablation techniques.
A Collaborative Effort
Dr. Andrea Natale, now a medical advisor, reiterated the importance of this exciting phase in electrophysiology, noting the increasing adoption of pulsed field ablation technologies that are elevating the standard of care. Her transition allows her to continue influencing clinical architecture while fostering innovation.
Championing Advances in Electrophysiology
Dr. Natale is renowned for his pioneering work at the Texas Cardiac Arrhythmia Institute and his role as National Medical Director of Cardiac Electrophysiology for HCA Healthcare, where he has been instrumental in groundbreaking treatments for atrial fibrillation and related arrhythmias.
Leadership Commitment to Quality
Burke T. Barrett, the President and CEO of Pulse Biosciences, expressed enthusiasm about the addition of Dr. Kenigsberg and Dr. Natale to the team. He emphasized how their expertise and experience will contribute to delivering high-quality clinical data, which is essential for illustrating the performance profile of the 360 catheter. He acknowledged the significant groundwork laid by Drs. Reddy and Koruth, emphasizing their vital contributions to the device's pre-clinical and clinical evaluations.
About Pulse Biosciences
Pulse Biosciences is at the forefront of bioelectric medicine, committed to advancing health innovation that positively impacts patient quality of life. The company’s nsPFA technology delivers precisely controlled nanosecond pulses of electrical energy intended to non-thermally clear targeted cells while preserving surrounding tissue integrity. Currently headquartered in Miami, Florida, with an additional office in Hayward, California, Pulse Biosciences is actively exploring applications of CellFX technology in atrial fibrillation treatments and other significant healthcare markets.
Frequently Asked Questions
What is the role of David Kenigsberg at Pulse Biosciences?
Dr. David Kenigsberg has been appointed as the Chief Medical Officer of Electrophysiology at Pulse Biosciences, tasked with leading clinical efforts related to innovative cardiac care technologies.
What technology does Pulse Biosciences specialize in?
Pulse Biosciences specializes in Nanosecond Pulsed Field Ablation™ technology, which utilizes brief and precise pulses of electrical energy for cardiac treatments.
Who are the key advisors for Pulse Biosciences?
The key advisors include Dr. Andrea Natale, Dr. Vivek Reddy, and Dr. Jacob Koruth, who are providing their expertise to advance the company's clinical efforts.
What is the significance of the 360 catheter?
The 360 catheter is a significant advancement in electrophysiology, demonstrating effectiveness in isolating pulmonary veins, which is crucial for improving treatments for atrial fibrillation.
How does Pulse Biosciences impact patient care?
Pulse Biosciences' innovative technologies aim to improve the quality of life for patients through advanced treatment options that minimize harm to surrounding non-cellular tissues.
